Revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Anika Therapeutics, Inc. (ANIK)
Price$20.81Cached quote
Net income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $112.8M | $119.9M | $120.8M | $113.8M | $147.8M | $130.5M | $114.6M | $105.6M | $113.4M | $103.4M | $93.0M | $105.6M | $75.1M | $71.4M | $64.8M | $55.6M | $40.1M |
| Gross profit | $63.8M | $76.0M | $82.5M | $73.2M | $82.9M | $69.0M | $85.9M | $74.3M | $86.1M | $79.4M | $71.9M | $84.7M | $52.3M | $42.4M | $38.0M | $31.7M | $26.5M |
| Gross margin | 56.56% | 63.38% | 68.33% | 64.33% | 56.12% | 52.91% | 74.92% | 70.37% | 75.87% | 76.76% | 77.36% | 80.18% | 69.68% | 59.38% | 58.65% | 57.11% | 65.94% |
| Research & development | $25.8M | $25.5M | $21.8M | $18.3M | $27.3M | $23.4M | $16.7M | $18.2M | $18.8M | $10.7M | $9.0M | $8.1M | $7.1M | $5.4M | $6.2M | $6.9M | $8.2M |
| Operating expenses | $74.9M | $81.1M | $81.7M | $69.5M | $80.3M | $97.3M | $80.4M | $83.8M | $67.7M | $52.8M | $44.9M | $44.1M | $42.5M | $51.6M | $50.8M | $48.0M | $34.5M |
| Operating income | −$11.1M | −$5.1M | $844,000 | $3.7M | $2.6M | −$28.3M | $34.2M | $21.7M | $45.7M | $50.6M | $48.1M | $61.4M | $32.6M | $19.7M | $14.0M | $7.5M | $5.6M |
| Operating margin | −9.80% | −4.25% | 0.70% | 3.22% | 1.77% | −21.71% | 29.88% | 20.60% | 40.32% | 48.95% | 51.76% | 58.19% | 43.43% | 27.63% | 21.56% | 13.57% | 13.92% |
| EBITDA | −$5.7M | $1.8M | $7.3M | $10.4M | $9.1M | −$22.2M | $39.2M | $27.7M | $50.0M | $54.3M | $51.9M | $66.2M | $37.4M | $24.2M | $18.0M | $10.9M | $6.9M |
| EBITDA margin | −5.03% | 1.49% | 6.03% | 9.11% | 6.15% | −17.05% | 34.21% | 26.20% | 44.10% | 52.56% | 55.82% | 62.65% | 49.78% | 33.97% | 27.74% | 19.54% | 17.14% |
| Net income | −$10.9M | −$56.4M | −$82.7M | −$14.9M | $4.1M | −$24.0M | $27.2M | $18.7M | $31.8M | $32.5M | $30.8M | $38.3M | $20.6M | $11.8M | $8.5M | $4.3M | $3.7M |
| Net profit margin | −9.64% | −47.02% | −68.44% | −13.05% | 2.80% | −18.38% | 23.73% | 17.74% | 28.05% | 31.48% | 33.07% | 36.29% | 27.40% | 16.48% | 13.07% | 7.77% | 9.19% |
| Basic EPSper basic share | -$0.76 | -$3.83 | -$5.64 | -$1.02 | $0.29 | -$1.69 | $1.93 | $1.30 | $2.18 | $2.22 | $2.06 | $2.61 | $1.46 | $0.89 | $0.65 | $0.34 | $0.32 |
| Diluted EPSper diluted share | -$0.76 | -$3.83 | -$5.64 | -$1.02 | $0.28 | -$1.69 | $1.89 | $1.27 | $2.11 | $2.15 | $2.01 | $2.51 | $1.39 | $0.82 | $0.62 | $0.32 | $0.32 |
Owners
Reported shareholders
10.83%of listed shares
BlackRock, Inc.1.45M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 10.83%1.45M shares |
Caligan Partners LP | 10.72%1.44M shares |
MORGAN STANLEY | 4.59%614.32K shares |
ACADIAN ASSET MANAGEMENT LLC | 4.53%606.54K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.27%572.11K shares |
AQR CAPITAL MANAGEMENT LLC | 4.18%559.85K shares |
BOOTHBAY FUND MANAGEMENT, LLC | 3.96%529.64K shares |
RENAISSANCE TECHNOLOGIES LLC | 3.60%481.42K shares |
DIMENSIONAL FUND ADVISORS LP | 3.37%451.1K shares |
CAPITAL MANAGEMENT CORP /VA | 3.35%448.47K shares |
DEUTSCHE BANK AG\ | 2.64%353.55K shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.48%331.58K shares |
STATE STREET CORP | 2.33%311.9K shares |
Blanchard Cheryl R | ≈2.02%270.53K shares |
TWO SIGMA INVESTMENTS, LP | 1.89%252.96K shares |
D. E. Shaw & Co., Inc. | 1.83%245.07K shares |
GOLDMAN SACHS GROUP INC | 1.78%237.72K shares |
JACOBS LEVY EQUITY MANAGEMENT, INC | 1.63%217.53K shares |
Nuveen, LLC | 1.17%156.54K shares |
Quantinno Capital Management LP | 1.16%155.26K shares |
Percentages use 13.38M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 1, 2026Form 4 | HENNEMAN JOHN B IIIDirector | BuyCommon Stock | 5.0K | $14.66 | $73.3K | 54.9K |
| Apr 30, 2026Form 4 | Griffin Stephen D.President and CEO | BuyCommon Stock | 12.2K | $12.29 | $149.9K | 36.2K |